GlassScriptPhysician profile
Shaden M Daloub
NPI 1679144281
$1,352.64
in general payments reported to CMS, 2019-2025
11 companies · $784 in 2025
The $784 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $569 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $375.86 | 2025 | Ensite Precision, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.49 | 2024-2025 | Lifevest |
| Boston Scientific Corporation | $157.03 | 2024-2025 | Watchman Flx, Zoom Wireless Transmitter |
| Abiomed | $141.55 | 2024 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $126.33 | 2024 | Arcalyst |
| Heartflow, INC. | $114.45 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $103.08 | 2024-2025 | Farxiga |
| Medtronic, INC. | $99.26 | 2024 | Resolute Onyx |
| Chiesi USA, INC. | $15.87 | 2025 | Kengreal |
| Novartis Pharmaceuticals Corporation | $15.44 | 2024 | |
| Novo Nordisk INC | $15.28 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaden Daloub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.